5-Aminolevulinic acid combined with ferrous iron improves glucose tolerance in high-fat diet-fed mice via upregulation of glucose transporter 1. 2021

Yasushi Kuroda, and Atsuko Kamiya, and Takuya Ishii, and Masahiro Ishizuka, and Yoko Yamashita, and Hitoshi Ashida
SBI Pharmaceuticals Co., Ltd., Tokyo 106-6020, Japan.

Decreased mitochondrial metabolism suppresses glucose metabolism, resulting in obesity and diabetes. The present study aimed to investigate mechanisms underlying the 5-aminolevulinic acid (5-ALA) hydrochloride-mediated increase in glucose uptake in high-fat diet (HFD)-fed mice in vivo and C2C12 myotube cells in vitro. C57BL/6N male mice (20 weeks old) were fed either HFD or normal diet (ND) for 4 weeks. A total of five HFD-fed mice were orally administered with 300 mg/kg 5-ALA hydrochloride and 47.1 mg/kg sodium ferrous citrate (SFC; HFD + 5-ALA/SFC), whereas ND and other HFD-fed mice were orally administered with saline. After 4 weeks, these mice were intraperitoneally administered with 2 g/kg glucose and 3.2 mg/kg 2-deoxyglucose (2DG) for intraperitoneal glucose tolerance test (IPGTT) and glucose uptake test. Body weights, plasma glucose levels and the area under the curve of IPGTT were lower in mice treated with HFD + 5-ALA/SFC compared with in those treated with HFD alone. 2DG uptake in the gastrocnemius muscle and heart were more significantly improved in the HFD + 5-ALA/SFC mice compared with the HFD-fed mice. Furthermore, 5-ALA/SFC increased 2DG uptake in C2C12 cells to a similar level to the insulin-treated group. Moreover, it increased glucose transport (GLUT)1 translocation in the plasma membrane by 2.5-fold relative to the controls without affecting GLUT1 expression; however, it had no effect on GLUT4 translocation. Therefore, 5-ALA/SFC enhanced gastrocnemius and cardiac glucose uptake in HFD-fed mice, and upregulated GLUT1 translocation to the plasma membrane, but not GLUT4 in C2C12 myotube cells. Therefore, it could potentially be used as a novel drug for the treatment of diabetes.

UI MeSH Term Description Entries

Related Publications

Yasushi Kuroda, and Atsuko Kamiya, and Takuya Ishii, and Masahiro Ishizuka, and Yoko Yamashita, and Hitoshi Ashida
November 2012, Toxicology and applied pharmacology,
Yasushi Kuroda, and Atsuko Kamiya, and Takuya Ishii, and Masahiro Ishizuka, and Yoko Yamashita, and Hitoshi Ashida
October 2018, Clinics (Sao Paulo, Brazil),
Yasushi Kuroda, and Atsuko Kamiya, and Takuya Ishii, and Masahiro Ishizuka, and Yoko Yamashita, and Hitoshi Ashida
April 2014, International immunopharmacology,
Yasushi Kuroda, and Atsuko Kamiya, and Takuya Ishii, and Masahiro Ishizuka, and Yoko Yamashita, and Hitoshi Ashida
August 2011, European journal of pharmacology,
Yasushi Kuroda, and Atsuko Kamiya, and Takuya Ishii, and Masahiro Ishizuka, and Yoko Yamashita, and Hitoshi Ashida
January 2019, Frontiers in endocrinology,
Yasushi Kuroda, and Atsuko Kamiya, and Takuya Ishii, and Masahiro Ishizuka, and Yoko Yamashita, and Hitoshi Ashida
June 2022, Food research international (Ottawa, Ont.),
Yasushi Kuroda, and Atsuko Kamiya, and Takuya Ishii, and Masahiro Ishizuka, and Yoko Yamashita, and Hitoshi Ashida
January 2011, PloS one,
Yasushi Kuroda, and Atsuko Kamiya, and Takuya Ishii, and Masahiro Ishizuka, and Yoko Yamashita, and Hitoshi Ashida
December 2009, Diabetes,
Yasushi Kuroda, and Atsuko Kamiya, and Takuya Ishii, and Masahiro Ishizuka, and Yoko Yamashita, and Hitoshi Ashida
May 2018, European journal of pharmacology,
Yasushi Kuroda, and Atsuko Kamiya, and Takuya Ishii, and Masahiro Ishizuka, and Yoko Yamashita, and Hitoshi Ashida
October 2014, Acta pharmacologica Sinica,
Copied contents to your clipboard!